Perhaps looking through rose coloured glasses, as I am a bit confused why there is no intinsic value added to ANP when a majority of the commercial risk as to potential development has / was removed at human clinical stage.
Why do I say that?
-we are basically at / near cash backing (admittedly high cash burn rate-but no cap raisings will be seen until human trials complete__ due q1: 2012 or earlier)
-we have a very good chance (95% ??) chance of commercial success, given success on primates
-we know our target market and can assume a minimum annual income of between 200 mill-500 mill at project launch, based on Somavert market share
-we have ISIS as a partner who have remained loyal and have the funds to assist us through growth / licensing with minimal dilution
-we will realise tax incentives / grants through all stages of development
When compared to ANY resource stock that is a small cap (speccy), I would argue we are WAY undervalued. I cant for the life of me understand why????
For analogy, I will use a recent stock recommended recently which is mining Potash
-It has just commenced drilling with known resource subsequent to previous historic drillings, thereby giving it some certainty / likelihood of success.
-It has to obtain state / federal grants (risk / timeframe)
-JORC (size of mine / mine life and thereby viability of commercialisation an unknown
-It will have environmental issues to respond to, additional risks of licensing, taxation, transportation, etc
YET, it has a current market cap of around 70mil and stated it may times x 5 if / when the state grants and
JORC is identified..At this point, you would consider it may have a timeline of 18-36 mths for development / commercialisation unless significant J/V established.
In my opinion, our little bio-tech has far less intrinsic risk.
If human trials are a success, one would assume a tie in partner would be chomping at the bit to be a part of this.
So, please inform me. Why would the market NOT realise our market cap be in the order of 600mill (3 x Projected earnings), upon finalisation of human trials???
Granted, we are and would remain as a small cap stock but at a SP of say 8cents, this still affords a great deal of growth / profit leading up to development where a market cap of 6 x P/E could not be out of the question.
To me, the only variables are:
. Success of human trials
. Time frame for sophisticated investors or tie in partner to jump on board
. Means / timeframes of cap raisings which will add further dilution to the S/P down the track
. What are the development costs through to commercialisation???
It's not a no brainer (why it's a speccy), but my money is happy to be in this stock rather than any current resource I am aware of given the risk / reward AND timeframes.
- Forums
- ASX - By Stock
- PER
- atl1103 anti cancer medications
atl1103 anti cancer medications, page-80
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.92M |
Open | High | Low | Value | Volume |
8.0¢ | 8.2¢ | 8.0¢ | $111.7K | 1.386M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 31160 | 8.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 21976 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 31160 | 0.081 |
1 | 42922 | 0.080 |
1 | 25278 | 0.079 |
2 | 30620 | 0.078 |
1 | 10000 | 0.077 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 21976 | 1 |
0.083 | 100000 | 1 |
0.084 | 160250 | 2 |
0.085 | 168500 | 2 |
0.086 | 291111 | 3 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online